The global cancer anorexia cachexia syndrome drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Cancer cachexia is a complex metabolic disease syndrome characterised by low body weight (particularly muscle mass) and anorexia in cancer patients. Cancer cachexia has been shown to have a major impact on patients' quality of life (QOL) and prognosis. The term cachexia refers to a loss of body mass, both lean and fat, as a result of a disease state, in this case cancer. Patients with such signs and symptoms have a shorter survival time, have a poor response to chemotherapeutic drugs, and are more toxic to agents. Furthermore, cancer anorexia/cachexia is frequently linked to weakness, weariness, and low quality of life. 

The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including partnerships and collaborations, mergers and acquisitions, geographical expansion, and new product launches, to remain competitive in the marketplace. For instance, Adlumiz (generic name: anamorelin hydrochloride) Tablet 50mg (Adlumiz), a ghrelin receptor agonist, was launched in Japan in April 2021 for the treatment of cancer cachexia in malignant tumors of non-small cell lung cancer, gastric cancer, pancreatic cancer, or colorectal cancer. Adlumiz is a ghrelin receptor agonist that is selective, unique, and orally active. The stomach secretes ghrelin, which is an endogenous peptide. Ghrelin stimulates several pathways in the positive regulation of body weight, muscle mass, hunger, and metabolism once it binds to its receptor. Adlumiz has been proven to increase body weight, the muscular mass, and hunger in cancer patients with cachexia.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2020-2028

Segment Covered- 

• By Product Type  
• By Distribution Channel 

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape- Ono Pharmaceutical Co., Ltd., and Pfizer Inc, among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
• Deviation from the pre-COVID-19 forecast
• Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Anorexia Cachexia Syndrome Drug Market Report by Segment

By Treatment Type 

• Progestogens
• Corticosteroids
• Combination therapies

By Distribution Channel 

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Anorexia Cachexia Syndrome Drug Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific 

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa